Literature DB >> 9013583

Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs.

J M Lehmann1, J M Lenhard, B B Oliver, G M Ringold, S A Kliewer.   

Abstract

Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) and cyclooxygenase inhibitor that is frequently used as a research tool to study the process of adipocyte differentiation. Treatment of various preadipocyte cell lines with micromolar concentrations of indomethacin in the presence of insulin promotes their terminal differentiation. However, the molecular basis for the adipogenic actions of indomethacin had remained unclear. In this report, we show that indomethacin binds and activates peroxisome proliferator-activated receptor gamma (PPARgamma), a ligand-activated transcription factor known to play a pivotal role in adipogenesis. The concentration of indomethacin required to activate PPARgamma is in good agreement with that required to induce the differentiation of C3H10T1/2 cells to adipocytes. We demonstrate that several other NSAIDs, including fenoprofen, ibuprofen, and flufenamic acid, are also PPARgamma ligands and induce adipocyte differentiation of C3H10T1/2 cells. Finally, we show that the same NSAIDs that activate PPARgamma are also efficacious activators of PPARalpha, a liver-enriched PPAR subtype that plays a key role in peroxisome proliferation. Interestingly, several NSAIDs have been reported to induce peroxisomal activity in hepatocytes both in vitro and in vivo. Our findings define a novel group of PPARgamma ligands and provide a molecular basis for the biological effects of these drugs on adipogenesis and peroxisome activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9013583     DOI: 10.1074/jbc.272.6.3406

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  255 in total

1.  Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs.

Authors:  D L Simmons; R M Botting; P M Robertson; M L Madsen; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

Review 2.  Genetic and pharmacological analysis of prostanoid receptor function.

Authors:  S Narumiya; G A FitzGerald
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

3.  Prostaglandin and PPAR control of immune cell function.

Authors:  Dino Rotondo; Jillian Davidson
Journal:  Immunology       Date:  2002-01       Impact factor: 7.397

4.  National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms.

Authors:  Daniel H Hwang; Victor Fung; Andrew J Dannenberg
Journal:  Neoplasia       Date:  2002 Mar-Apr       Impact factor: 5.715

5.  Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo.

Authors:  M T Heneka; T Klockgether; D L Feinstein
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

6.  Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death.

Authors:  Y F Guan; Y H Zhang; R M Breyer; L Davis; M D Breyer
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

7.  Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate.

Authors:  X M Xu; L Sansores-Garcia; X M Chen; N Matijevic-Aleksic; M Du; K K Wu
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

Review 8.  Diet, fatty acids, and regulation of genes important for heart disease.

Authors:  John P Vanden Heuvel
Journal:  Curr Atheroscler Rep       Date:  2004-11       Impact factor: 5.113

9.  Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma.

Authors:  L Chastine Bell-Parikh; Tomomi Ide; John A Lawson; Peter McNamara; Muredach Reilly; Garret A FitzGerald
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

10.  Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut.

Authors:  Salvatore Cuzzocrea; Barbara Pisano; Laura Dugo; Angela Ianaro; Nimesh S A Patel; Rosanna Di Paola; Tiziana Genovese; Prabal K Chatterjee; Massimo Di Rosa; Achille P Caputi; Christoph Thiemermann
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.